FDA delays decision on Gilead's HIV drug; Amgen drug flunks late-stage CKD study

@FierceBiotech: Merck Serono staffers mull strike as budget ax hovers over Geneva HQ. Item | Follow @FierceBiotech

@RyanMFierce: Hi all, we're about to launch FierceBiotech's Fierce 15 biotech search. Countdown from 10... Survey | Follow @RyanMFierce

> BioSante preps for two more PhIII LibiGel trials. News

> ADA roundup: J&J's diabetes pioneer edges out Januvia in Phase III. More

> Gilead Sciences says the FDA has delayed its decision on whether it will allow Truvada to be sold as a guard against HIV infection. Report

> Amgen ($AMGN) says Sensipar failed a late stage study among chronic kidney disease patients. The drug failed to significantly reduce the risk of death and cardiovascular incidents. Report

> Sanofi says it has filed for approval of its diabetes drug lixisenatide in Japan. Story

> Newton, MA-based Chiasma says it has raised $3 million in debt financing. Story

Pharma News

@FiercePharma: J&J to pay up to $2.2bn in Risperdal settlement, Bloomberg says. Close to Pfizer's record $2.3bn deal. More | Follow @FiercePharma

> Now it's generic versions of Pfizer's ($PFE) blockbuster cholesterol pill Lipitor that are seeing sales erosion--from other generics. News

> Roche ($RHHBY) isn't planning to make a second run at Illumina, the gene-sequencing company it tried to buy earlier this year, and plans to look at smaller deals instead. Report

> Novartis ($NVS) announced new data suggesting that its Gilenya multiple-sclerosis pill was effective at reducing relapses and reducing the loss of brain volume in MS patients, with a "consistent safety profile." Story

> Germany's new drug-pricing system is keeping new medicines out of patients' hands, a European pharma association contends. Item

> Mylan ($MYL) and Teva Pharmaceutical Industries ($TEVA) came to an agreement over generic Provigil, in a deal that allows Mylan to launch its version Aug. 10, before Teva's 180-day exclusivity period expires. Article

> GlaxoSmithKline ($GSK) told the World Anti-Doping Agency that its experimental anti-anemia drug could also be used by athletes as a performance enhancer. More

> Japan's Astellas Pharma launched Dificlir, a treatment for Clostridium dificile infections, in the European market. Report

> Clinigen Group, a U.K.-based drugmaker that licenses pharma's mature or end-of-lifecycle drugs, is looking to sell itself or go public, Sky News reports. News

> FDA approves Roche's pricey new Herceptin partner, Perjeta. Story

Medical Device News

@FierceMedDev: Get your nominations in for the 15 fiercest private medical device developers while there is still time. Survey | Follow @FierceMedDev

> ECG-maker AliveCor pulls in $10.5M. More

> ConforMIS, an orthopedics implant maker, seeks $68M. Article

> Boston Sci closes $150M deal for Cameron, new ICD. News

> J&J's Animas will advance a second artificial pancreas trial. Story

Biotech IT News

> Biogen vet tapped as CIO of Harvard Med School. News

> Pharma rocks many Twitter handles for many reasons. More

> Novartis predicts drug side effects with computers. Report

> Lilly leads docs to cancer drug trials with iPad app. Item

And Finally… A team of UCLA stem cell scientists say that a purified subset of stem cells found in fat tissue was able to form bone that was better and faster than current methods produce. Release

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.